Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Myosin Therapeutics General Information
MT-125 has received FDA orphan drug designation for malignant gliomas and is entering Phase 1b trials for glioblastoma. MT-110 is advancing to Phase 1 clinical trials for methamphetamine use disorder.
Contact Information
Primary Industry
Biotech
Corporate Office
Jupiter, Florida
United States
United States
Drug Pipeline
MT-125
Phase 1Key Partnerships
Mayo Clinic
Myosin Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Mar 25, 2026 | $2.0M | Completed | Phase 1 |
To view Myosin Therapeutics's complete valuation and funding history, request access »